Boiron SA (BOI) AI Stock Analysis

• Market Cap: €395.92M
• Dividend Yield: 4.63%
• Average Volume (3M): 1.60K
• Price to Earnings (P/E): 34.6
• Beta (1Y): -0.06
• Revenue Growth: -1.15%
• EPS Growth: -68.36%
• Country: FR
• Employees: 2,469
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 17,545,408
• 10 Day Avg. Volume: 1,199
• 30 Day Avg. Volume: 1,604
• PEG Ratio: -0.73
• Price to Book (P/B): 1.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: €24.50 ▲(8.41%Upside)

Boiron SA faces several challenges, particularly with declining revenue and operational efficiency. While the balance sheet remains strong, the technical indicators and high valuation relative to earnings suggest caution. The dividend yield is a positive factor, but overall, the stock presents moderate risk with limited upside in the current environment.

Boiron SA Business Overview & Revenue Model

Company Description

Boiron SA (BOI) is a French pharmaceutical company that specializes in the production and distribution of homeopathic products. Established in 1932, the company operates in the healthcare sector, offering a wide range of homeopathic medicines and supplements designed to support health and wellness. Boiron is recognized for its commitment to quality and innovation in the field of homeopathy, with a global presence that includes subsidiaries and distribution networks in multiple countries.

How the Company Makes Money

Boiron SA generates revenue primarily through the sale of its homeopathic products, which include over-the-counter remedies and healthcare supplements. The company's revenue model is centered around its extensive product portfolio that caters to various health needs, such as allergy relief, pain management, and cold and flu symptoms. Boiron leverages its global distribution network to reach pharmacies, healthcare practitioners, and consumers. The company also invests in marketing and education to increase awareness and acceptance of homeopathy as an alternative or complementary healthcare option. Partnerships with healthcare professionals and ongoing research and development efforts contribute to maintaining and expanding its market presence, thereby driving sales and revenue growth.

Boiron SA Financial Statement Overview

Summary

Boiron SA presents a stable balance sheet with low leverage, but faces challenges in revenue growth and profitability. Cash flow generation is strong, but declining trends need attention. Focus should be on reversing revenue decline and improving operational efficiencies.

Income Statement

Boiron SA's income statement shows a decline in total revenue from 2022 to 2024, dropping from €534.2M to €487.6M. The gross profit margin has remained relatively stable, while the net profit margin shows a significant decrease due to declining net income. The company has maintained positive EBIT and EBITDA margins, though both have decreased over the past few years, indicating a reduction in operational efficiency. Overall, the company is facing challenges in maintaining its top-line growth and profitability.

Balance Sheet

The balance sheet of Boiron SA indicates a strong equity position with a debt-to-equity ratio that is very low, showcasing financial stability and low leverage risk. The equity ratio is robust, reflecting good asset management and financial health. However, the declining trend in stockholders' equity and total assets since 2022 suggests potential challenges in asset growth and equity retention.

Cash Flow

Boiron SA's cash flow statement reveals a slight decline in free cash flow over recent years, with a noticeable decrease in both operating cash flow and capital expenditures. The free cash flow to net income ratio remains healthy, indicating strong cash generation relative to profit. However, declining trends in free cash flow growth rate highlight potential concerns in sustaining cash flow levels in the future.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	487.56M	493.25M	534.24M	455.20M	513.58M
Gross Profit	358.76M	358.08M	379.73M	327.62M	394.74M
EBITDA	45.46M	73.67M	91.33M	78.75M	68.91M
Net Income	11.34M	35.83M	44.67M	28.56M	26.21M
Balance Sheet
Total Assets	576.33M	590.20M	789.49M	770.70M	781.82M
Cash, Cash Equivalents and Short-Term Investments	64.71M	74.04M	250.94M	234.50M	234.69M
Total Debt	14.97M	13.70M	22.17M	12.61M	12.43M
Total Liabilities	198.15M	198.70M	232.15M	238.93M	272.65M
Stockholders Equity	378.14M	393.66M	557.62M	531.74M	509.14M
Cash Flow
Free Cash Flow	33.77M	27.47M	41.51M	13.46M	47.98M
Operating Cash Flow	42.17M	45.49M	60.10M	33.88M	68.68M
Investing Cash Flow	-18.36M	-22.93M	-15.28M	-11.92M	-19.34M
Financing Cash Flow	-30.49M	-198.41M	-28.99M	-22.56M	-21.93M

Boiron SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Negative. The current price of 22.6 is below the 20-day moving average (MA) of 22.71, below the 50-day MA of 23.02, and below the 200-day MA of 25.32, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 42.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BOI.

Boiron SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VETO	76 Outperform	€903.52M	15.36	10.64%	1.16%	1.88%	5.79%
BOI	62 Neutral	€395.92M	34.61	2.94%	4.63%	-1.15%	-68.36%
Sector *	55 Neutral	€4.86B	18.25	-49.50%	1.91%	13.92%	-4.82%
ABVX	52 Neutral	€431.55M	―	-148.98%	―	―	18.52%
AB	49 Neutral	€97.21M	―		―	10.52%	30.56%
IVA	42 Neutral	€364.81M	―		―	-47.37%	-26.56%
MEDCL	37 Underperform	€556.88M	―		―	-1.66%	-6.31%